GMT20260402 015843 Recording 1366x768

Introduction to Testicular Cancer

Overview of the Presentation

• Dr. Alexis Sánchez introduces himself as a urologist from the Hospital Nacional Edgardo Rodale T. Martins and sets the stage for discussing testicular cancer.

Epidemiology of Testicular Cancer

• Testicular cancer accounts for 1-1.5% of neoplasms in males and 5% of tumors, with an incidence rate of 3 to 10 new cases per 100,000 men annually in Western countries.

• Only 1-2% of cases are bilateral at diagnosis; about 5% have extra-gonadal primary sites, often within the abdomen.

Incidence and Prevalence

• Globally, it is the most common tumor type among males aged 15 to 35 years; in Peru, it ranks as the 22nd most frequent cancer with approximately 582 cases per year.

• The prevalence is noted at around 12 per 10,000 inhabitants with a mortality rate of about 82 deaths annually.

Types and Classification of Testicular Tumors

Histological Types

• The majority (90-95%) are germ cell tumors; non-seminomatous tumors peak in incidence during the third decade while pure seminomas peak in the fourth decade.

Subtypes Explained

• Germ cell tumors can be classified into seminomas (classic, anaplastic, spermatocytic) and non-seminomatous types (embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma).

Etiology and Risk Factors

Genetic Alterations

• Chromosomal abnormalities are present in all germ cell tumors; specifically alterations on chromosome arm short arm of chromosome 12 are significant.

Major Risk Factors

• Key risk factors include history of cryptorchidism (undescended testes), Klinefelter syndrome, family history (first-degree relatives), contralateral testicular neoplasia, and infertility.

Clinical Presentation and Diagnosis

Symptoms to Watch For

• Common symptoms include unilateral scrotal mass that is usually painless; trauma may reveal underlying masses.

Diagnostic Imaging Techniques

• Ultrasound is crucial for confirming tumor presence; MRI may be used if ultrasound results are inconclusive but not routinely required.

Tumor Characteristics and Metastasis

Lateralization Insights

• Right testicle involvement occurs more frequently (57%) than left due to higher rates of cryptorchidism on that side; bilaterality occurs in only about 2–3%.

Signs & Symptoms Related to Metastasis

• A nodule or swelling is present in approximately 90% of cases; other symptoms may include pain resembling epididymitis or hydrocele formation.

Physical Examination Techniques

Importance of Examination

• A thorough physical examination includes bimanual palpation starting with the contralateral healthy testicle before examining the affected one for consistency and characteristics.

Diagnostic Markers

Tumor Markers Utilized

• Important markers include lactate dehydrogenase (LDH), alpha-fetoprotein (AFP), and beta-human chorionic gonadotropin (beta-HCG); imaging aids like chest X-rays or CT scans help assess metastasis.

Diagnostic Imaging for Testicular Masses

Ultrasound and Its Importance

• A high-frequency testicular ultrasound (over 10 MHz) is essential for diagnosing testicular masses and assessing retroperitoneal abdominal masses, including potential metastasis.

• The ultrasound can also evaluate levels of alpha-fetoprotein and beta-HCG to determine the presence of tumors.

Role of Tomography

• Contrast-enhanced tomography of the abdomen and pelvis is crucial for identifying visceral and lymphatic metastases, with a sensitivity of 67% and a positive predictive value of 87%.

• Chest tomography aids in evaluating supradiaphragmatic lymph nodes and pulmonary nodules, boasting a sensitivity of 100%.

When to Use MRI

• MRI should be requested when ultrasound results are inconclusive or if the patient has an allergy to contrast agents.

• It is also useful in cases where brain or spinal metastases are suspected, particularly with elevated beta-HCG levels above 5,000.

Sensitivity and Specificity of Diagnostic Tools

Ultrasound Efficacy

• Ultrasound demonstrates a sensitivity of 100% and specificity between 95%-100%, confirming testicular lesions while allowing evaluation of the contralateral testicle.

• It helps identify hypoechoic or heterogeneous lesions as well as microcalcifications.

Tumor Markers in Diagnosis

Importance of Tumor Markers

• Tumor markers increase by 51%, but negative markers do not exclude diagnosis; key markers include beta-HCG, alpha-fetoprotein, and lactate dehydrogenase.

• Beta-HCG is elevated in all carcinomas (100%), half of embryonal carcinomas (50%), and about one-third (30%) in seminomas.

Alpha-Fetoprotein Insights

• Alpha-fetoprotein has a half-life of 5 to 7 days; normal serum levels should be below 15 ng/mL.

• Effective therapy will normalize serum levels within four half-lives (20 to 28 days), but false positives can occur due to various malignancies.

Understanding Lactate Dehydrogenase

Characteristics and Implications

• Lactate dehydrogenase indicates tissue destruction; it’s elevated in advanced tumors (80%) but can also rise due to non-malignant conditions.

• This enzyme's elevation correlates with tumor volume; it has a half-life of approximately 24 hours.

Distinguishing Between Germ Cell Tumors

Classic Seminoma Overview

• Classic seminoma accounts for about 85% of germ cell tumors, typically affecting men aged 30–40 years.

• It appears as a homogeneous hypoechoic nodule on ultrasound.

Non-Seminomatous Tumors

Embryonal Carcinoma Insights

• Embryonal carcinoma represents about 20–25% among germ cell tumors. They may elevate HSG due to trophoblastic cells present.

Teratoma Characteristics

• Teratomas are lobulated tumors that may contain gelatinous material; they can be mature or immature based on differentiation level.

Overview of Testicular Tumors and Their Characteristics

Types of Tumors

• Alfa-fetoprotein Levels: Elevated in 90% of cases, with a 10-20% occurrence of metastases and 40% hematogenous spread.

• Coriocarcinoma: Represents less than 1% of cases; primarily affects ages 20-25, elevating beta-HCG to 99%, but never alfa-fetoproteins. Highly aggressive with significant hematogenous metastasis.

Diagnosis and Imaging Techniques

• Diagnostic Approach: Essential to perform staging studies after initial diagnosis, including CT scans for thorax and abdomen. Suspected metastases may require cranial MRI or bone scintigraphy.

• CT Scan Sensitivity: Offers a sensitivity of 70-80% and specificity of 95-100%. Nodes over 10mm are considered positive for metastasis. A comprehensive thoraco-abdominopelvic scan is recommended for better mediastinal sensitivity.

Understanding Lymphatic Drainage and Metastasis

Lymphatic Drainage Patterns

• Right Testicle Drainage: Drains predominantly to the left (10-15%), affecting para-aortic nodes; left testicle drainage is less frequent (<5%).

• Inguinal and Pelvic Metastases: Can occur due to invasion into the vaginal tunic or scrotal skin, especially post-surgical alterations like hernias or biopsies that disrupt lymphatic flow.

Staging Classifications

• Tumor Classification (T):

• T1: Limited to testis/epididymis without vascular/lymphatic invasion.

• T2: Vascular/lymphatic invasion present.

• T3/T4: Invasion beyond tunica albuginea into spermatic cord/scrotum respectively.

Prognostic Factors in Germ Cell Tumors

Metastasis Classification

• Nodal Involvement (N):

• N1: Nodes <2cm.

• N2: Nodes between 2cm and <5cm.

• N3: Nodes >5cm indicating advanced disease stage.

Overall Staging Importance

• M0 indicates no distant metastasis; M1 signifies presence with subcategories based on regional involvement (M1A/B). This classification aids in determining clinical stages for treatment planning based on tumor markers at diagnosis.

Treatment Strategies for Testicular Cancer

Initial Surgical Intervention

• Radical Orchiectomy: The primary surgical approach should be performed within one week post-diagnosis; emergency surgery is not advised unless absolutely necessary within this timeframe. Avoid scrotal approaches due to higher local recurrence rates compared to inguinal orchiectomy (0.4% vs 2.9%).

Adjuvant Treatments

• For patients undergoing scrotal surgery, adjuvant radiation therapy should include ipsilateral groin and scrotum areas in seminoma cases, while non-seminomatous germ cell tumors require extensive excision during retroperitoneal lymphadenectomy procedures if affected by scarring from previous surgeries.

Surgical Considerations in Testicular Cancer Treatment

Importance of Surgical Techniques

• Patients undergoing platinum-based chemotherapy should have the cord stump removed during retroperitoneal lymphadenectomy. Pre-surgery, patients must be asked about their preference for testicular prosthesis placement.

• In cases with poor general health or extensive disease spread, resection may be postponed until after chemotherapy if the biological profile aligns with germ cell tumor diagnosis.

Treatment Approaches Based on Tumor Characteristics

• The choice between conservative treatment (tumorectomy or partial orchiectomy) is influenced by clinical markers and patient history, particularly in bilateral tumors or those with a single testicle.

• Radical orchiectomy is the cornerstone of diagnosis and treatment for testicular neoplasms, confirming histopathological diagnosis and local tumor staging.

Surgical Procedure Details

• The surgical incision is approximately two centimeters above the pubic tubercle, extending five centimeters laterally to cover the inguinal canal. This technique minimizes morbidity and achieves effective tumor control.

• After incising through layers, the external ring is identified; below it lies the spermatic cord which must be carefully dissected from the inguinal canal to peritoneal reflection.

Handling Spermatic Cord During Surgery

• Proper dissection of the spermatic cord is crucial before extracting the testicle via inguinal route. Vascular safety measures are necessary due to significant blood supply risks.

• The deferent ducts and gonadal vessels are clamped and ligated with non-absorbable sutures while leaving a long tail for future identification.

Screening and Self-examination Recommendations

Importance of Testicular Self-examination

• There are no high-evidence studies supporting routine screening programs for testicular cancer; however, young men should be educated on self-examination's significance.

• High-risk groups such as those with a history of cryptorchidism or personal/family cancer histories should prioritize regular self-examinations.

Treatment Strategies Based on Histology and Stage

• For stage 1 seminomas, low-risk patients may only require observation or radiotherapy; high-risk patients need immediate chemotherapy options like carboplatin AUC.

Chemotherapy Protocol for Advanced Stages

Recommended Chemotherapy Regimens

• Stage 2A/B typically requires four cycles of cisplatin/etoposide or three cycles of bleomycin/etoposide/cisplatin. Recurrences are treated similarly to stage 3 protocols.

Tailored Treatments Based on Risk Levels

• Radiotherapy can target para-aortic chains in certain cases; recurrence management follows established chemotherapy guidelines for stage 3 treatments.

Individualized Treatment Plans

Customizing Patient Care

• Systemic treatment for seminomas varies by initial disease stage, achieving up to 100% cure rates in stage 1. Discussions regarding individualization based on patient circumstances are essential.

Monitoring Low-Risk Patients

• Low-risk patients (tumors <4 cm without rete testis invasion), may undergo close monitoring due to a relapse risk around 10%. High-risk individuals (>4 cm or invasive tumors), will likely receive adjuvant chemotherapy.

Alternative Treatments When Chemotherapy Is Contraindicated

Options Beyond Standard Chemotherapy

• In cases where bleomycin poses risks (e.g., pulmonary issues), alternative regimens like TIP (paclitaxel/cisplatin/ifosfamide over four cycles), can be considered instead of standard BEP therapy.

Special Considerations for Older Patients

• For older patients (>70 years), radiotherapy might be preferred when second malignancy risks are lower compared to younger cohorts facing aggressive treatments.

This structured markdown file provides an organized overview of key insights from the transcript related to surgical techniques, treatment strategies, screening recommendations, and individualized care approaches in managing testicular cancer.

Seguimiento y Tratamiento de Ganglios Linfáticos

Progresión y Tratamiento Inicial

• Se continuará el seguimiento en caso de regresión de los ganglios, considerando una hematomía retroperitoneal si no hay cambios radiológicos.

• Si hay progresión con marcadores positivos, se puede indicar B por tres ciclos más; si son negativos, se opta por la infedectomía.

Ciclos de Quimioterapia

• En estadios 2B y C y E3, el tratamiento estándar es BEP; el número de ciclos depende de la clasificación pronóstica.

• Para pacientes con buen pronóstico, se recomiendan tres ciclos de BEP; para intermedio o mal pronóstico, cuatro ciclos. La dosis máxima acumulada de blomicina debe ser 400 por 10,000 unidades.

Manejo Post Quimioterapia

Tratamiento de Masa Residual

• Después de quimioterapia, se realiza linfoderectomía retroperitoneal estándar en pacientes con enfermedad diseminada y marcadores tumorales negativos.

• En seminomas con masa residual menor a 3 cm, generalmente no contienen tumor viable; mayores a 3 cm pueden tener entre un 13% y un 30% de masa viable.

Exámenes Especiales

• Se solicitará un PET scan para masas residuales mayores a 3 cm seis semanas después del tratamiento; un resultado positivo indica necesidad quirúrgica.

• En tumores no seminomatosos, el rendimiento del PET scan es bajo; cirugía indicada para masas residuales mayores a un centímetro con marcadores negativos.

Intervención Quirúrgica

Procedimientos según Resultados

• Si la anatomía patológica muestra teratoma maduro tras cirugía en masas residuales, se opta por seguimiento; si hay más del 10% de enfermedad viable, se administran dos ciclos adicionales de quimioterapia.

• Las cirugías pueden realizarse vía abierta o laparoscópica dependiendo del tamaño y extensión de las lesiones residuales.

Tumores Testiculares Adicionales

Neoplasia Intratubular

• La biopsia contralateral solo debe realizarse en pacientes con antecedentes específicos como criptorquidia o volumen testicular reducido (menos de 12 cc).

• El tratamiento para neoplasia intratubular incluye radioterapia en fracciones específicas (20 grays). También pueden presentarse tumores como los células Leydig que tienen una incidencia notable entre la tercera y sexta década.

Seguimiento Post-Tratamiento

Grupos Definidos para Seguimiento

• Los grupos incluyen: seminoma estadio I, estadio I no seminomatoso en vigilancia activa y aquellos que han recibido tratamiento adyuvante curativo para enfermedad metastásica con remisión completa o parcial.

Recomendaciones Generales

• Para seminomas estadio I: marcadores tumorales cada seis meses durante los primeros tres años; tomografía abdominopélvica dos veces al año durante los primeros dos años luego anualmente hasta cinco años post-tratamiento.

Estrategias Específicas

• Estadio I no seminomatoso requiere seguimiento más estricto: marcadores cuatro veces al año durante los primeros dos años y tomografías programadas similarmente a lo anterior pero ajustadas según riesgo individualizado hasta cumplir cinco años post-tratamiento.

Alta Médica

Consideraciones Finales

• Tanto pacientes con tumores germinales seminomatosos como no seminomatosos recibirán alta médica a los diez años pero deben ser informados sobre riesgos potenciales como residuos tardíos o desarrollo de segundas neoplasias que requieren seguimiento anual posterior al alta médica.